Filipa Pedro

Filipa Pedro

Auto-generated profile, based on publicly available information

Filipa Pedro

Unidade de Doenças Auto-Imunes/Medicina 7.2, Hospital de Curry Cabral, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
AOAna Alves Oliveira
Ana Alves Oliveira
FPFilipa Pedro
Filipa Pedro
NCNuno Craveiro
Nuno Craveiro
ACAna Vera Cruz
Ana Vera Cruz
RARaquel Sousa Almeida
Raquel Sousa Almeida
CSCristina Santos
Cristina Santos
SUMMARY Sodium polystyrene sulfonate (PSP) or Kayexalate is a cation-exchange resin, widely used in the management of hyperkalaemia due to renal disease. A rare, yet potentially dangerous, adverse event related to sodium polystyrene sulfonate use is intestinal mucosal injury, especially in the colon. The injury to the gastrointestinal mucosa can range from mild and superficial to wall necrosis and bowel perforation. The mechanism that leads to mucosal damage remains unclear. However, it is believed that sorbitol, commonly given to counteract PSP’s tendency to cause constipation, may play an important role in the development of gastrointestinal injury. Other potential risk factors are uraemia or end-stage renal disease, hemodynamic instability, solid organ transplantation, postoperative status and concomitant opioid administration. The authors present a case of diarrhoea and haematochezia after the administration of PSP without sorbitol, in a patient with hyperkalaemia due to acute kidney injury, in the absence of other risk factors. A colonoscopy was performed and revealed a rectal ulcer which histological findings were suggestive of mucosal injury due to Kayexalate deposition. This case supports the concept that this widely used drug can itself, without sorbitol, cause injury to the gastrointestinal wall. Even though this is a rare adverse effect, the widespread use of this medication may put a large population at risk.

10 November 2022 in International Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
MMMaria Francisca Moraes-Fontes
Maria Francisca Moraes-Fontes
FPFilipa Pedro
Filipa Pedro
MCMaria Manuel Campos
Maria Manuel Campos
MFMelissa Fernandes
Melissa Fernandes
SYSule Yavuz
Sule Yavuz
APAntónio Panarra
António Panarra
Objective. We aimed to identify features that allow differentiation of primary antiphospholipid syndrome (PAPS) patients that suffer recurrent thrombotic events (RTE) despite anticoagulation, from the other diagnosed PAPS patients. Methods. This was an exploratory study of anticoagulated PAPS patients attending an Autoimmune Diseases Unit (1998-2018). From 2016, anti-phospholipid antibodies and lupus anticoagulant were determined for each patient at consecutive visits, collected together with retrospective clinical characteristics, laboratory, and therapeutic markers and compared according to the occurrence of thrombotic events during follow-up. Results. Overall, two thirds of the patients were female, 93 were Caucasian, with a median age of 40 years at diagnosis, for a median time of 11.5 years in follow-up. Out of 54 patients, 10 were identified with RTE. There were no significant differences among the RTE and non-RTE patients as far as classical risk factors for clotting disorders. The RTE group was characterized by a higher proportion of younger patients, male sex and positivity for all laboratory markers, and initially and over follow-up as well as a sustained high-risk profile based on APS laboratory markers. Anticardiolipin IgG at onset was the only statistically significant marker of the RTE group. At the end of follow-up, consistent reversion to negative status was a rare event, observed in 20 of RTE vs. 25 of non-RTE patients. Conclusions. Despite therapy, we were able to identify features associated to thrombotic events in patients with PAPS. Prospectively regular clinical and laboratory monitoring might be warranted in order to treat APS more assertively.

1 July 2018 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
FPFilipa Pedro
Filipa Pedro
YAYahia Abuowda
Yahia Abuowda
NCNuno Craveiro
Nuno Craveiro
AOAna Alves Oliveira
Ana Alves Oliveira
AMAna Mestre
Ana Mestre
CSCristina Santos
Cristina Santos
SUMMARY The authors report a case of a 69-year-old man with idiopathic leukocytoclastic cutaneous vasculitis. For three years, the lesions recurred with progressive worsening and were associated with systemic manifestations of low-grade fever, weight loss and raised inflammatory markers. The patient latter presented a 6th cranial nerve involvement, raising the concern of a possible systemic vasculitis, which was latter evidenced by the development of deep vein thrombosis and angina pectoris. The treatment of the patient witch based on the decreasing of inflammatory activity, by using effective immunosuppressive therapy, with lower toxicity is more important than identifying the type of the vasculitis. This case illustrates the importance of awareness for the systemic involvement that can occur in up to 50% of patients with leukocytoclastic cutaneous vasculitis.